Alkem Laboratories profit falls 22% in Q1FY27 despite 11% revenue growth
Alkem Laboratories posted a 10.9% YoY revenue increase to ₹37,402 million in Q1FY27, buoyed by 34.5% growth in non-US international sales and 10.3% domestic growth. However, net profit dropped 21.7% to ₹5,200 million as EBITDA margins contracted to 20.5% from 21.9%, impacted by higher R&D spend and operating cost pressures.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories reported a significant year-on-year decline in consolidated net profit for the first quarter of FY27 (ended June 30, 2026). Net profit fell 21.7% to ₹5,200 million from ₹6,643 million in the corresponding period last year. This decline occurred despite an 10.9% growth in revenue from operations, which rose to ₹37,402 million from ₹33,711 million in Q1FY26.
The divergence between top-line growth and bottom-line contraction highlights persistent pressure on operating efficiency. EBITDA grew modestly by 3.7% to ₹7,661 million from ₹7,391 million, but the EBITDA margin contracted significantly by 140 basis points to 20.5% from 21.9% in the prior year quarter. This margin compression indicates that cost structures or mix shifts are eroding profitability faster than revenue expansion can offset.
Financial Performance
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue from Operations: | ₹37,402 million | ₹33,711 million | +10.9% |
| EBITDA: | ₹7,661 million | ₹7,391 million | +3.7% |
| EBITDA Margin: | 20.5% | 21.9% | -140 bps |
| Net Profit: | ₹5,200 million | ₹6,643 million | -21.7% |
On a standalone basis, Alkem Laboratories reported a net profit of ₹5,699.8 million for continuing operations, down from ₹6,222.6 million in Q1FY26. Standalone revenue from operations for continuing operations rose 12.5% to ₹26,677.3 million from ₹23,721.7 million. The standalone results exclude discontinued operations related to the Generic Business, which was transferred to wholly owned subsidiary Alkem Wellness Limited effective October 1, 2025.
Geographic and Segment Highlights
Domestic business sales grew 10.3% year-on-year to ₹24,978 million, contributing 67.1% to total sales. According to IQVIA (SSA) data, Alkem registered a volume/value growth of 13.2% year-on-year, outperforming the Indian Pharmaceutical Market (IPM) growth of 12.2% by 100 basis points. The company outperformed the market in seven key therapy areas, including Anti-infectives, Gastro-intestinal, and Pain management.
International sales rose 16.0% to ₹12,223 million. This was driven by robust growth in non-US markets, where sales surged 34.5% to ₹4,785 million from ₹3,556 million. US business sales grew more moderately by 6.5% to ₹7,439 million. During the quarter, the company received five ANDA approvals in the US, including one tentative approval.
Strategic Developments and Tax Regime
The Board of Directors, in its meeting held on August 14, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. A key strategic update is the company's decision to opt for the new tax regime under Section 115BAA of the Income-tax Act, 1961, starting from FY27. This decision follows amendments introduced under the Finance Act, 2026, allowing the set-off of available Minimum Alternate Tax (MAT) credit under the new regime. Consequently, tax expense for the current quarter has been recognized based on enacted rates applicable under the new regime.
Additionally, the Group, through its wholly owned subsidiary Alkem Medtech Private Limited, acquired a majority stake in Occlutech Holding AG, Switzerland, on July 16, 2026. As this acquisition was completed subsequent to the end of the reporting quarter, it has no impact on the consolidated financial results for Q1FY27.
What the Numbers Show
The primary analytical observation is the sharp divergence between revenue growth and net profit performance. While Alkem Laboratories managed to grow its consolidated top line by nearly 11%, net profit fell by over 21%. This disconnect is driven by the compression in EBITDA margins, which failed to keep pace with revenue expansion. Furthermore, R&D expenses increased significantly to ₹1,502 million (4.0% of revenue) from ₹1,184 million (3.5% of revenue) in the prior year quarter, indicating higher investment intensity that weighed on operating margins. The data indicates that while demand supports sales volume, particularly in non-US international markets, input costs or pricing pressures are impacting operating leverage, leading to a notable erosion in profitability at both operating and bottom-line levels.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.50% | -4.10% | -3.57% | -0.64% | -0.38% | +46.77% |
How will the shift to the new tax regime under Section 115BAA impact Alkem's effective tax rate and long-term cash flows compared to the previous regime?
What specific cost-control measures or pricing strategies is Alkem implementing to reverse the 140 basis point contraction in EBITDA margins?
How is the recent acquisition of a majority stake in Occlutech Holding AG expected to diversify revenue streams and offset profitability pressures in the core pharma business?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
